LUNG: Revenue growth returned as adjusted EBITDA loss nearly halved and FY guidance held

Pulmonx Corporation reported Q3 2026 revenue growth in U.S. and international markets, with adjusted EBITDA loss decreasing by nearly 60%. The company maintained FY 2026 revenue guidance of $90M–$92M, citing cost discipline and sales-team productivity.

Original reporting
Published Oct 27, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
LUNG: Revenue growth returned as adjusted EBITDA loss nearly halved and FY guidance held — source image
Decision brief

The 30-second read

$LUNGBullishMed
01

Why it matters

The earnings beat and guidance reaffirmation could trigger a short‑term rally, especially in after‑hours trading.

02

Market read

First‑time Q3 earnings disclosure for LUNG provides fresh data that may move the stock.

03

What to watch

Potential competitive pressure and reimbursement uncertainties not addressed in the release.

Relevance 7/10Novelty 7/10Timing: after‑hours release

Background

Pulmonx Corp (LUNG) reported Q3 2026 earnings, showing a return to YoY revenue growth and a 60% reduction in adjusted EBITDA loss, while reaffirming FY revenue guidance.

Company-level read

Ticker impact

$LUNGBullishHigh confidence
Context

Q3 2026 results show revenue growth and EBITDA loss narrowed 60%, with FY guidance reaffirmed at $90M‑$92M.

Expected impact

likely upside as investors price in stronger top‑line and narrowed loss.

Evidence & confidence

First‑time disclosure of Q3 numbers and guidance for a micro‑cap; market typically reacts positively to revenue growth and EBITDA improvement.

Market effects

Signals improving demand in the pulmonary medical devices sector.

May boost sentiment for US biotech micro‑caps.

Limited to niche medical device investors.

Counterpoint

Revenue growth may be unsustainable; guidance still modest, could limit upside.

Key entities

  • Pulmonx Corporation

    US‑listed medical device maker focused on pulmonary therapies.

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.